YourLawyer.com 1-800-LAW-INFO (1-800-529-4636)

Parker Waichman Alonso LLP Headlines by Topic

Tysabri

Tysabri PML Cases Get Attention of European Drug Agency

Aug 14, 2008 | Parker Waichman Alonso LLP
European health regulators are taking a hard look at two cases of a potentially lethal brain infection linked to the drug Tysabri.  About 31,800...

Tysabri Lawsuit to Stay in State Court

Aug 8, 2008 | Parker Waichman Alonso LLP
A lawsuit over injuries allegedly caused by  the multiple sclerosis drug, Tysabri, is staying in Massachusetts  state court.  The...

Tysabri Linked to More Cases of PML

Aug 1, 2008 | Parker Waichman Alonso LLP
Tysabri has been implicated in two more cases of a deadly brain infection, raising new concerns about the safety of the multiple sclerosis...

Tysabri Now Linked to Severe Liver Damage

Feb 27, 2008 | Parker Waichman Alonso LLP
Tysabri, a controversial drug used to treat Multiple Sclerosis (MS) manufactured by Biogen Idec Inc. and Elan Corp. has been linked to serious liver...

Tysabri Waltzes through FDA Advisory Panel by 12-0

Mar 9, 2006 | Newsinferno News Staff
When sales of Tysabri were suspended on February 28, 2005, many critics of the highly controversial MS drug, with potentially fatal side-effects,...

Tysabri - Opponents of MS Drug Linked to Potentially Fatal Brain Disease Locked In Emotional Debate with Desperate Patients before FDA Advisory Panel

Mar 8, 2006 | Newsinferno News Staff
Normally, the decision as to whether a prescription drug should be approved for marketing is based on scientific evidence and clinical studies....

FDA Official Still Wary About MS Drug

Mar 7, 2006 | AP
Some patients who take a promising multiple sclerosis drug will likely die of a rare brain infection if the medicine, Tysabri, is allowed back on the...

Anti-inflammatory Drugs Potentially Deadly Side Effect Found To Be Rare

Mar 3, 2006 | www.sciencedaily.com
Scientists have completed an extensive study of more than 3,000 patients who received a promising anti-inflammatory drug, natalizumab, that was...

Doctors wary of Biogen MS drug, survey says

Mar 1, 2006 | Boston Globe
Shares in Biogen Idec Inc. and Elan Corp. fell sharply yesterday after a Wall Street analyst published the results of a survey suggesting doctors...

Elan Stung by Research Report

Feb 28, 2006 | www.thestreet.com
Tysabri, the multiple sclerosis drug from Biogen Idec (BIIB:Nasdaq) and Elan (ELN:NYSE ADR) , should return to the market but with strict limitations...

Page 1/3 [first] [prev] 1 2 3 [next] [last]

Tysabri
* Denotes required field.

Title

* First Name

* Last Name

* Email Address

* Phone Number

Cell Phone Number

Office Phone Number

Street Address

Apartment/Suite

City

State

Zip Code

Please provide the best method and times to contact you:

Date of birth of person injured
(mm-dd-yyyy):

Date you started taking the drug (mm-yyyy):

Date you stopped taking the drug (mm-yyyy):

Please describe any side effects:

Other Info:

No Yes, I agree to the Parker Waichman Alonso LLP disclaimers.Click here to review all.

Yes, I would like to receive the Parker Waichman Alonso LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Home | Defective Drugs | Medical Devices | Toxic Substances | Accidents | Product Liability | Malpractice | Diseases
Nursing Home Negligence | Food Poisoning | Other Topics | Contact
Statement of Clients' Rights | Site Map | ReNu with MoistureLoc | Vioxx | Mesothelioma | Permax | Dostinex | Composix Kugel Mesh X Large Patch
Ortho Evra | Fosamax | Personal Injury Lawyer | Fusarium Keratitis | Stevens Johnson Syndrome

© 2002-2008 YourLawyer.com. All Rights Reserved.

Please note that you are not considered a client until you have signed a retainer agreement and your case has been accepted by us.
Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Attorney Advertising

Parker Waichman Personal Injury News